Zanolimumab: Difference between revisions
Content deleted Content added
Citation bot (talk | contribs) Add: s2cid. | Use this bot. Report bugs. | Suggested by Obama gaming | Category:Monoclonal antibodies | #UCB_Category 47/306 |
Citation bot (talk | contribs) Alter: title. | Use this bot. Report bugs. | Suggested by BrownHairedGirl | #UCB_webform 1226/2066 |
||
| Line 45: | Line 45: | ||
| molecular_weight = 147 kg/mol |
| molecular_weight = 147 kg/mol |
||
}} |
}} |
||
'''Zanolimumab''' (expected trade name '''HuMax-CD4'''<ref>[http://www.genmab.com/PressCentre/ArchivedNewsReleases/2000/GenmabInitiatesPhaseIIStudyWithHuMax-CD4/Language/English.aspx Genmab initiates Phase II Study with HuMax-CD4] {{webarchive |url=https://web.archive.org/web/20080516135546/http://www.genmab.com/PressCentre/ArchivedNewsReleases/2000/GenmabInitiatesPhaseIIStudyWithHuMax-CD4/Language/English.aspx |date=May 16, 2008 }}</ref>) is a [[human]] [[monoclonal antibody]] and an [[immunosuppressive drug]].<ref name="Mestel_2008">{{cite journal | vauthors = Mestel DS, Beyer M, Möbs M, Steinhoff M, Sterry W, Assaf C | title = Zanolimumab, a human monoclonal antibody targeting CD4 in the treatment of mycosis fungoides and Sézary syndrome | journal = Expert Opinion on Biological Therapy | volume = 8 | issue = 12 | pages = 1929–39 | date = December 2008 | pmid = 18990079 | doi = 10.1517/14712590802528696 | s2cid = 58115371 }}</ref> It was developed with the goal of treatment of [[rheumatoid arthritis]], [[psoriasis]], [[melanoma]],<ref>{{cite web|url=http://www.tenxbiopharma.com/development.shtml |title= |
'''Zanolimumab''' (expected trade name '''HuMax-CD4'''<ref>[http://www.genmab.com/PressCentre/ArchivedNewsReleases/2000/GenmabInitiatesPhaseIIStudyWithHuMax-CD4/Language/English.aspx Genmab initiates Phase II Study with HuMax-CD4] {{webarchive |url=https://web.archive.org/web/20080516135546/http://www.genmab.com/PressCentre/ArchivedNewsReleases/2000/GenmabInitiatesPhaseIIStudyWithHuMax-CD4/Language/English.aspx |date=May 16, 2008 }}</ref>) is a [[human]] [[monoclonal antibody]] and an [[immunosuppressive drug]].<ref name="Mestel_2008">{{cite journal | vauthors = Mestel DS, Beyer M, Möbs M, Steinhoff M, Sterry W, Assaf C | title = Zanolimumab, a human monoclonal antibody targeting CD4 in the treatment of mycosis fungoides and Sézary syndrome | journal = Expert Opinion on Biological Therapy | volume = 8 | issue = 12 | pages = 1929–39 | date = December 2008 | pmid = 18990079 | doi = 10.1517/14712590802528696 | s2cid = 58115371 }}</ref> It was developed with the goal of treatment of [[rheumatoid arthritis]], [[psoriasis]], [[melanoma]],<ref>{{cite web|url=http://www.tenxbiopharma.com/development.shtml |title=TenX BioPharma |access-date=August 20, 2010 |url-status=dead |archive-url=https://web.archive.org/web/20100411114420/http://www.tenxbiopharma.com/development.shtml |archive-date=April 11, 2010 }}</ref> cutaneous and peripheral [[T-cell lymphoma]].<ref>[http://www.ama-assn.org/ama1/pub/upload/mm/365/zanolimumab.doc Statement On A Nonproprietary Name Adopted By The USAN Council - Zanolimumab], ''American Medical Association''.</ref><ref>{{ClinicalTrialsGov|NCT00042406|Trial With HuMax-CD4 in Patients With Rheumatoid Arthritis Failing Treatment With Methotrexate and a TNF-Alpha Blocker}}</ref> Development of the drug was ultimately discontinued with termination of all trials.<ref>{{cite web|title=Status of clinical trials for Zanolimumab|url=http://clinicaltrials.gov/search/intervention=Zanolimumab|access-date=6 November 2011}}</ref> |
||
== References == |
== References == |
||
Revision as of 18:54, 20 August 2022
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Human |
| Target | CD4 |
| Clinical data | |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Molar mass | 147 kg/mol |
  (what is this?) (verify) | |
Zanolimumab (expected trade name HuMax-CD4[1]) is a human monoclonal antibody and an immunosuppressive drug.[2] It was developed with the goal of treatment of rheumatoid arthritis, psoriasis, melanoma,[3] cutaneous and peripheral T-cell lymphoma.[4][5] Development of the drug was ultimately discontinued with termination of all trials.[6]
References
- ^ Genmab initiates Phase II Study with HuMax-CD4 Archived May 16, 2008, at the Wayback Machine
- ^ Mestel DS, Beyer M, Möbs M, Steinhoff M, Sterry W, Assaf C (December 2008). "Zanolimumab, a human monoclonal antibody targeting CD4 in the treatment of mycosis fungoides and Sézary syndrome". Expert Opinion on Biological Therapy. 8 (12): 1929–39. doi:10.1517/14712590802528696. PMID 18990079. S2CID 58115371.
- ^ "TenX BioPharma". Archived from the original on April 11, 2010. Retrieved August 20, 2010.
- ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Zanolimumab, American Medical Association.
- ^ Clinical trial number NCT00042406 for "Trial With HuMax-CD4 in Patients With Rheumatoid Arthritis Failing Treatment With Methotrexate and a TNF-Alpha Blocker" at ClinicalTrials.gov
- ^ "Status of clinical trials for Zanolimumab". Retrieved 6 November 2011.
 | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |
 | This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |